Login to Your Account



Takeda Offers $106.3M to Back Heptares' Schizophrenia Leads

By Nuala Moran


Tuesday, April 12, 2011
LONDON – Heptares Therapeutics Ltd. signed a deal worth a potential £65 million (US$106.3 million) with Takeda Pharmaceutical Co., to characterize the structure and deliver early leads against a G-protein coupled receptor (GPCR) that is involved in schizophrenia.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription